Miach Orthopaedics
Privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, with initial focus on the Bridge-Enhanced™ ACL Repair (BEAR™) Implant.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $20.0m Valuation: $150m | Series B | |
| Total Funding | 000k | ||
Related Content
Miach Orthopaedics is a medical device company focused on bio-engineered surgical implants for connective tissue restoration. The company's core product is the Bridge-Enhanced ACL Restoration (BEAR) Implant, a technology developed to treat anterior cruciate ligament (ACL) tears.
The BEAR Implant is the first FDA-approved medical technology that enables the body to heal its own torn ACL. Unlike traditional ACL reconstruction, which involves replacing the torn ligament with a graft, the BEAR Implant acts as a bridge to help the ends of the torn ACL heal back together. This approach preserves the patient's native tissue, avoids the complications associated with graft harvesting from other parts of the body, and supports a faster recovery.
The company's business model centers on the sale of this proprietary medical device to hospitals and surgical centers. Its primary clients are orthopedic surgeons specializing in sports medicine. Miach Orthopaedics operates in the competitive orthopedic medical device market, offering a differentiated solution for one of the most common knee injuries.
Keywords: ACL repair, orthopedic implants, medical devices, connective tissue, surgical technology, bio-engineering, sports medicine, knee surgery, ligament restoration, tissue healing